Cargando…

Clostridium difficile: Diagnosis and the Consequence of Over Diagnosis

Clostridium difficile infection (CDI) is a leading cause of healthcare-associated infections, accounting for significant disease burden and mortality. The clinical spectrum of C. difficile ranges from asymptomatic colonization to toxic megacolon and fulminant colitis. CDI is characterized by new ons...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Helen S., Plechot, Kamryn, Gohil, Shruti, Le, Jennifer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8116462/
https://www.ncbi.nlm.nih.gov/pubmed/33770398
http://dx.doi.org/10.1007/s40121-021-00417-7
_version_ 1783691399338655744
author Lee, Helen S.
Plechot, Kamryn
Gohil, Shruti
Le, Jennifer
author_facet Lee, Helen S.
Plechot, Kamryn
Gohil, Shruti
Le, Jennifer
author_sort Lee, Helen S.
collection PubMed
description Clostridium difficile infection (CDI) is a leading cause of healthcare-associated infections, accounting for significant disease burden and mortality. The clinical spectrum of C. difficile ranges from asymptomatic colonization to toxic megacolon and fulminant colitis. CDI is characterized by new onset of ≥ 3 unformed stools in 24 h and is confirmed by laboratory test for the presence of toxigenic C. difficile. Currently, laboratory tests to diagnose CDI include toxigenic culture, glutamate dehydrogenase (GDH), nucleic acid amplification test (NAAT), and toxins A/B enzyme immunoassay (EIA). The sensitivities of these tests are variable with toxin EIA ranging from 53 to 60% and with NAAT at about 95%. Overall, the specificity is > 90% for these methods. However, the positive predictive value (PPV) depends on the disease prevalence with lower CDI rates associated with lower PPVs. Notably, the widespread use of the highly sensitive NAAT and its relatively lower clinical specificity have led to overdiagnosis of C. difficile by identifying carriers when NAAT is used as the sole diagnostic method. Overdiagnosis of C. difficile has resulted in unwarranted treatment, possibly attributing to resistance to metronidazole and vancomycin, increased risk for overgrowth of vancomycin-resistant enterococci strains in stool specimens, and increased hospitalization thereby impacting patient safety and healthcare costs. Strategies to optimize the clinical sensitivity and specificity of current laboratory tests are critical to differentiate the clinical CDI from colonization. To achieve high diagnostic yield, if preagreed institutional criteria for stool submission are not used, a multistep approach to CDI diagnosis is recommended, such as either GDH or NAAT followed by toxins A/B EIA in conjunction with laboratory stewardship by evaluating C. difficile test orders for appropriateness and providing feedback. Furthermore, antimicrobial stewardship, along with provider education on appropriate testing for C. difficile, is vital to differentiate CDI from colonization.
format Online
Article
Text
id pubmed-8116462
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-81164622021-05-14 Clostridium difficile: Diagnosis and the Consequence of Over Diagnosis Lee, Helen S. Plechot, Kamryn Gohil, Shruti Le, Jennifer Infect Dis Ther Review Clostridium difficile infection (CDI) is a leading cause of healthcare-associated infections, accounting for significant disease burden and mortality. The clinical spectrum of C. difficile ranges from asymptomatic colonization to toxic megacolon and fulminant colitis. CDI is characterized by new onset of ≥ 3 unformed stools in 24 h and is confirmed by laboratory test for the presence of toxigenic C. difficile. Currently, laboratory tests to diagnose CDI include toxigenic culture, glutamate dehydrogenase (GDH), nucleic acid amplification test (NAAT), and toxins A/B enzyme immunoassay (EIA). The sensitivities of these tests are variable with toxin EIA ranging from 53 to 60% and with NAAT at about 95%. Overall, the specificity is > 90% for these methods. However, the positive predictive value (PPV) depends on the disease prevalence with lower CDI rates associated with lower PPVs. Notably, the widespread use of the highly sensitive NAAT and its relatively lower clinical specificity have led to overdiagnosis of C. difficile by identifying carriers when NAAT is used as the sole diagnostic method. Overdiagnosis of C. difficile has resulted in unwarranted treatment, possibly attributing to resistance to metronidazole and vancomycin, increased risk for overgrowth of vancomycin-resistant enterococci strains in stool specimens, and increased hospitalization thereby impacting patient safety and healthcare costs. Strategies to optimize the clinical sensitivity and specificity of current laboratory tests are critical to differentiate the clinical CDI from colonization. To achieve high diagnostic yield, if preagreed institutional criteria for stool submission are not used, a multistep approach to CDI diagnosis is recommended, such as either GDH or NAAT followed by toxins A/B EIA in conjunction with laboratory stewardship by evaluating C. difficile test orders for appropriateness and providing feedback. Furthermore, antimicrobial stewardship, along with provider education on appropriate testing for C. difficile, is vital to differentiate CDI from colonization. Springer Healthcare 2021-03-26 2021-06 /pmc/articles/PMC8116462/ /pubmed/33770398 http://dx.doi.org/10.1007/s40121-021-00417-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Review
Lee, Helen S.
Plechot, Kamryn
Gohil, Shruti
Le, Jennifer
Clostridium difficile: Diagnosis and the Consequence of Over Diagnosis
title Clostridium difficile: Diagnosis and the Consequence of Over Diagnosis
title_full Clostridium difficile: Diagnosis and the Consequence of Over Diagnosis
title_fullStr Clostridium difficile: Diagnosis and the Consequence of Over Diagnosis
title_full_unstemmed Clostridium difficile: Diagnosis and the Consequence of Over Diagnosis
title_short Clostridium difficile: Diagnosis and the Consequence of Over Diagnosis
title_sort clostridium difficile: diagnosis and the consequence of over diagnosis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8116462/
https://www.ncbi.nlm.nih.gov/pubmed/33770398
http://dx.doi.org/10.1007/s40121-021-00417-7
work_keys_str_mv AT leehelens clostridiumdifficilediagnosisandtheconsequenceofoverdiagnosis
AT plechotkamryn clostridiumdifficilediagnosisandtheconsequenceofoverdiagnosis
AT gohilshruti clostridiumdifficilediagnosisandtheconsequenceofoverdiagnosis
AT lejennifer clostridiumdifficilediagnosisandtheconsequenceofoverdiagnosis